What is MS Phase 3 Fingolimod FREEDOMS?

Category: Others


Generic name: Fingolimod Clinical Trial

See also: Clinical Trial

NCT00289978 is a completed 24-month, double-blind, randomized study comparing the efficacy and safety of fingolimod 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Other study names are ID#CFTY720D2301 and FREEDOMS.

Last updated:
There are no evaluations for MS Phase 3 Fingolimod FREEDOMS.